On September 10, 2026, Amgen Inc. (AMGN) received a “Hold” rating from HSBC analyst Morten Herholdt, reflecting a more cautious stance on the pharmaceutical giant’s stock moving forward. This rating comes as Amgen’s shares trade at $391.27, suggesting a potential upside to the analyst’s price target of $445. For investors, this rating signals a pause in bullish momentum, warranting a closer look at the company’s fundamentals and market performance amid a complex market landscape.
Recent Price Action
Amgen’s stock has experienced noticeable fluctuations in the recent trading sessions. Currently priced at $391.27, the stock has declined by approximately 2.27% from the prior trading day, which indicates a change of $8.74. This drop occurs against a backdrop of moderate trading activity, with a volume of roughly 1.19 million shares exchanged, significantly lower than its average volume of 2.71 million shares. Over the last year, AMGN has oscillated between a 52-week low of $45.10 and a high of $445, showcasing its volatility. The stock possesses a beta of 0.426, indicating it tends to be less volatile than the broader market, an aspect that may appeal to conservative investors.
[chart type=’price’ value=’AMGN’]
Historical Performance
Amgen’s recent historical performance tells a more nuanced story. Over the past month, the stock has gained 1.53%, while its quarterly performance stands at 10.77%, demonstrating resilience amidst market variances. Over a 12-month horizon, AMGN’s performance has been even more impressive, marked by a 22.85% gain. While the weekly volatility is pegged at 2.27% and monthly volatility at 2.07%, these fluctuations should be interpreted in the context of broader market volatility and sector-specific developments. Comparatively, average volume over the last ten days shows an uptick at 2.8 million, reflective of investor interest despite the recent ratings change.
[chart type=’performance’ value=’AMGN’]
Earnings Analysis
Examining Amgen’s most recent earnings report reveals a notable earnings surprise, providing some context to its current valuation. For the quarter ending August 4, 2026, Amgen reported an earnings-per-share (EPS) of $6.29, significantly outpacing the market’s estimate of $5.62 by about 11.92%. This contrasts starkly with its prior quarter where the EPS fell short of expectations, marking a -28.75% surprise with a reported EPS of $3.37 against an estimate of $4.73. Such a volatile earnings history accentuates the unpredictability associated with Amgen’s financial performance, although the latest results may instill renewed confidence among investors looking for solid returns.
[chart type=’income-bar-chart’ value=’AMGN’]
Consensus Ratings
The overall sentiment on Amgen reveals a mixed yet cautious outlook from analysts. Based on recent consensus data, there are 20 ratings for the stock, of which 9 are categorized as “Buy”, while a larger segment, 11, maintains a “Hold” position, with no analysts issuing a “Sell” recommendation. The average price target stands at $405, with a high of $460 and a low of $303, suggesting substantial diversity in analyst forecasts. Although the latest rating from HSBC aligns with a more conservative “Hold,” it underscores the potential for price appreciation based on the established price targets.
[chart type=’analyst-ratings’ value=’AMGN’]
Stock Grading and Fundamental View
Amgen holds an ST Score of 48, indicative of moderate strength in its underlying financial and market health. This score assesses various categories that encompass revenue growth, profitability, and overall market position, providing a rounded view of its investment profile. While not indicative of leading sector performance, this score suggests that Amgen remains a viable entity within its industry, particularly for investors focused on long-term stability rather than aggressive growth.
[chart type=’st-cards’ value=’AMGN’]
Conclusion
For potential investors, Amgen presents an intriguing case amid the shifting landscape of pharmaceutical stocks. While the Hold rating reflects a cautious approach and current price underperformance, the potential upside outlined by analysts warrants attention, especially those seeking to capitalize on moderate growth. With strong recent earnings performance and a detailed consensus suggesting resilience, Amgen could appeal to long-term investors. However, prospective buyers should remain vigilant of market dynamics and inherent risks tied to pharmaceutical developments and regulatory shifts. Given the company’s substantial market cap and lower volatility profile, it remains an attractive option for investors with a balanced risk tolerance looking to maintain an equity stake in the life sciences sector.